Tvardi Therapeutics is trading 5.18% higher at $1.93, moving alongside a broadly stronger U.S. market.
- The S&P 500, Nasdaq Composite, and Dow Jones Industrial Average are each up more than 1%, supporting risk appetite across equities.
- No new company-specific announcement dated September 11, 2026 was identified.
- Recent investor-conference appearances and prior clinical updates are not clear same-day catalysts.